[{"id":"87b1ddb1-88bf-432d-ae10-124f4071cf19","acronym":"NECTARINE","url":"https://clinicaltrials.gov/study/NCT07192991","created_at":"2025-09-27T08:39:02.695Z","updated_at":"2025-09-27T08:39:02.695Z","phase":"","brief_title":"Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America","source_id_and_acronym":"NCT07192991 - NECTARINE","lead_sponsor":"Latin American Cooperative Oncology Group","biomarkers":" DLL3","pipe":"","alterations":" ","tags":["DLL3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/03/2025","start_date":" 11/03/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-09-25"},{"id":"66ccecbb-fe4e-496e-997f-7e4c2aa7798b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07080242","created_at":"2025-07-26T13:29:22.344Z","updated_at":"2025-07-26T13:29:22.344Z","phase":"Phase 1","brief_title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","source_id_and_acronym":"NCT07080242","lead_sponsor":"SystImmune Inc.","biomarkers":" DLL3","pipe":"","alterations":" ","tags":["DLL3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-07-23"},{"id":"164a11b6-0a88-4e66-b764-a14af3e3880e","acronym":"NCI-2018-01054","url":"https://clinicaltrials.gov/study/NCT03360721","created_at":"2021-01-18T16:35:16.869Z","updated_at":"2025-02-25T12:26:48.752Z","phase":"Phase 2","brief_title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT03360721 - NCI-2018-01054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" AR overexpression • AR expression • AR-V7 expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR overexpression • AR expression • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-24"},{"id":"29940bae-2e04-4198-8582-ee2667059194","acronym":"","url":"https://clinicaltrials.gov/study/NCT06406465","created_at":"2024-05-11T04:14:20.188Z","updated_at":"2025-02-25T12:30:34.309Z","phase":"Phase 2","brief_title":"A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity","source_id_and_acronym":"NCT06406465","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2025-02-24"},{"id":"2a09abe0-6495-491d-a75a-5fe8da47ac10","acronym":"","url":"https://clinicaltrials.gov/study/NCT04086485","created_at":"2021-01-18T20:00:12.098Z","updated_at":"2025-02-25T12:27:19.621Z","phase":"Phase 1/2","brief_title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","source_id_and_acronym":"NCT04086485","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["BRCA • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/03/2022","start_date":" 10/03/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-24"},{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"c5926a3c-11fc-4d8b-a13e-2af41702c630","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866382","created_at":"2021-01-18T19:04:09.999Z","updated_at":"2025-02-25T12:37:16.517Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","source_id_and_acronym":"NCT03866382","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/13/2019","start_date":" 05/13/2019","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-24"},{"id":"5ca3f586-5d57-495c-9088-bac9d19c4782","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826341","created_at":"2021-04-01T16:52:34.686Z","updated_at":"2025-02-25T13:40:26.267Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","source_id_and_acronym":"NCT04826341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-21"},{"id":"2a6d7e4f-c35c-4e6b-8dc6-72106bb36c61","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750954","created_at":"2023-12-06T16:15:46.614Z","updated_at":"2025-02-25T13:53:37.832Z","phase":"Phase 1","brief_title":"Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT04750954","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/22/2021","start_date":" 07/22/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-20"},{"id":"5b783b7c-5a42-40ed-b63a-61150837a02a","acronym":"A021804","url":"https://clinicaltrials.gov/study/NCT04394858","created_at":"2021-01-29T07:20:43.079Z","updated_at":"2025-02-25T13:53:17.999Z","phase":"Phase 2","brief_title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","source_id_and_acronym":"NCT04394858 - A021804","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MGMT • CD4","pipe":"","alterations":" ","tags":["MGMT • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-20"},{"id":"e8b91e71-29e4-4b49-a8d1-038d6c000854","acronym":"HPN328-4001","url":"https://clinicaltrials.gov/study/NCT04471727","created_at":"2021-01-18T21:29:07.037Z","updated_at":"2025-02-25T12:37:38.530Z","phase":"Phase 1/2","brief_title":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","source_id_and_acronym":"NCT04471727 - HPN328-4001","lead_sponsor":"Harpoon Therapeutics, Inc., a subsidiary of Merck \u0026 Co., Inc. (Rahway, New Jersey USA)","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)"],"overall_status":"Recruiting","enrollment":" Enrollment 232","initiation":"Initiation: 12/14/2020","start_date":" 12/14/2020","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-20"},{"id":"5949ed40-8066-4fa3-b731-56d11b1c4969","acronym":"MRT-2359-001","url":"https://clinicaltrials.gov/study/NCT05546268","created_at":"2022-09-19T13:55:51.266Z","updated_at":"2025-02-25T14:17:16.661Z","phase":"Phase 1/2","brief_title":"Study of Oral MRT-2359 in Selected Cancer Patients","source_id_and_acronym":"NCT05546268 - MRT-2359-001","lead_sponsor":"Monte Rosa Therapeutics, Inc","biomarkers":" MYC • MYCN","pipe":" | ","alterations":" MYCN amplification • MYC expression","tags":["MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • MRT-2359"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-17"},{"id":"fdfd9de7-291d-41f6-a1e7-37009f68c58e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665739","created_at":"2021-01-19T20:43:36.156Z","updated_at":"2025-02-25T14:15:45.821Z","phase":"Phase 2","brief_title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","source_id_and_acronym":"NCT04665739","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • everolimus • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 02/03/2023","start_date":" 02/03/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-17"},{"id":"2487ddb2-7738-4021-b64c-94036379e85b","acronym":"CHAMP","url":"https://clinicaltrials.gov/study/NCT04709276","created_at":"2021-01-19T20:52:08.240Z","updated_at":"2025-02-25T14:29:51.192Z","phase":"Phase 2","brief_title":"A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04709276 - CHAMP","lead_sponsor":"Andrew J. Armstrong, MD","biomarkers":" TP53 • PTEN • RB1 • SYP","pipe":" | ","alterations":" LDH elevation","tags":["TP53 • PTEN • RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-14"},{"id":"39be432b-e1d2-4ded-8099-18c4960548fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06805825","created_at":"2025-02-25T15:15:39.171Z","updated_at":"2025-02-25T15:15:39.171Z","phase":"Phase 1","brief_title":"A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit","source_id_and_acronym":"NCT06805825","lead_sponsor":"Novelty Nobility, Inc.","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NN3201"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 02/03/2025","start_date":" 02/03/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-13"},{"id":"9c0791f2-df06-44ae-99f3-11a3ceff187a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496208","created_at":"2021-01-18T12:02:15.721Z","updated_at":"2025-02-25T15:10:16.692Z","phase":"Phase 1","brief_title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","source_id_and_acronym":"NCT02496208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/22/2015","start_date":" 07/22/2015","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"67176e4e-5f06-435a-a426-189730ad7d5a","acronym":"LITESPARK-015","url":"https://clinicaltrials.gov/study/NCT04924075","created_at":"2021-07-05T17:36:40.354Z","updated_at":"2025-02-25T15:26:55.556Z","phase":"Phase 2","brief_title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","source_id_and_acronym":"NCT04924075 - LITESPARK-015","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KIT • PDGFRA • VHL • EPAS1","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA • VHL • EPAS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Welireg (belzutifan)"],"overall_status":"Recruiting","enrollment":" Enrollment 322","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 06/04/2029","primary_completion_date":" 06/04/2029","study_txt":" Completion: 06/04/2029","study_completion_date":" 06/04/2029","last_update_posted":"2025-02-11"},{"id":"a1ad25fe-9fca-497e-84b3-6dc3bccd8870","acronym":"CHM-2101-001","url":"https://clinicaltrials.gov/study/NCT06055439","created_at":"2023-09-26T16:12:30.309Z","updated_at":"2025-02-25T15:45:14.681Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","source_id_and_acronym":"NCT06055439 - CHM-2101-001","lead_sponsor":"Chimeric Therapeutics","biomarkers":" CDH17","pipe":" | ","alterations":" CDH1 expression","tags":["CDH17"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 05/15/2024","start_date":" 05/15/2024","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-11"},{"id":"066dc8ea-37cf-470d-bcfd-d29caadd354e","acronym":"STRATUS","url":"https://clinicaltrials.gov/study/NCT06717243","created_at":"2025-02-25T15:29:58.607Z","updated_at":"2025-02-25T15:29:58.607Z","phase":"","brief_title":"Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)","source_id_and_acronym":"NCT06717243 - STRATUS","lead_sponsor":"Oncology Center of Biochemical Education And Research","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 02/20/2025","start_date":" 02/20/2025","primary_txt":" Primary completion: 03/20/2028","primary_completion_date":" 03/20/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-10"},{"id":"11565097-46a7-40c4-bd2e-84aac455986c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01638533","created_at":"2021-01-18T07:02:41.766Z","updated_at":"2025-02-25T14:33:33.086Z","phase":"Phase 1","brief_title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","source_id_and_acronym":"NCT01638533","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • AFP","pipe":"","alterations":" ","tags":["ER • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/03/2012","start_date":" 08/03/2012","primary_txt":" Primary completion: 11/29/2018","primary_completion_date":" 11/29/2018","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2025-02-07"},{"id":"84573df1-6556-4bd1-8122-88ef0fa3cd96","acronym":"","url":"https://clinicaltrials.gov/study/NCT05879978","created_at":"2023-05-30T14:05:15.128Z","updated_at":"2025-02-25T16:33:29.735Z","phase":"Phase 1/2","brief_title":"A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","source_id_and_acronym":"NCT05879978","lead_sponsor":"Boehringer Ingelheim","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e obrixtamig (BI 764532) • ezabenlimab (BI 754091)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/28/2023","start_date":" 07/28/2023","primary_txt":" Primary completion: 09/05/2025","primary_completion_date":" 09/05/2025","study_txt":" Completion: 09/05/2025","study_completion_date":" 09/05/2025","last_update_posted":"2025-02-07"},{"id":"dff546be-9a9d-4936-8524-d7a95d167ef0","acronym":"FORESEE","url":"https://clinicaltrials.gov/study/NCT06406387","created_at":"2024-05-09T20:29:53.236Z","updated_at":"2025-02-25T16:34:09.927Z","phase":"","brief_title":"ATRX/DAXX in EUS-FNB Specimens of Pan-NETs","source_id_and_acronym":"NCT06406387 - FORESEE","lead_sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","biomarkers":" ATRX • DAXX","pipe":"","alterations":" ","tags":["ATRX • DAXX"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 03/30/2025","primary_completion_date":" 03/30/2025","study_txt":" Completion: 11/30/2029","study_completion_date":" 11/30/2029","last_update_posted":"2025-02-07"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"4be67477-813c-4d4a-afcc-f5d5c110e3d8","acronym":"ReLUTH","url":"https://clinicaltrials.gov/study/NCT04954820","created_at":"2021-07-08T14:52:46.401Z","updated_at":"2025-02-25T16:45:28.459Z","phase":"Phase 2","brief_title":"Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET","source_id_and_acronym":"NCT04954820 - ReLUTH","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 10/01/2031","primary_completion_date":" 10/01/2031","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2025-02-06"}]